S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

Fresenius SE & Co KGaA Stock Price, Forecast & Analysis (FRA:FRE)

€48.39
+0.23 (+0.48 %)
(As of 11/18/2019 04:00 PM ET)
Add
Today's Range
€48.12
Now: €48.39
€49.08
50-Day Range
€40.74
MA: €44.78
€49.02
52-Week Range
€60.16
Now: €48.39
€80.00
Volume1.31 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+49-6172-6080

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive FRE News and Ratings via Email

Sign-up to receive the latest news and ratings for FRE and its competitors with MarketBeat's FREE daily newsletter.


Fresenius SE & Co KGaA (FRA:FRE) Frequently Asked Questions

What is Fresenius SE & Co KGaA's stock symbol?

Fresenius SE & Co KGaA trades on the FRA under the ticker symbol "FRE."

What price target have analysts set for FRE?

19 analysts have issued 12-month price targets for Fresenius SE & Co KGaA's stock. Their forecasts range from €43.00 to €78.00. On average, they expect Fresenius SE & Co KGaA's stock price to reach €55.84 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price. View Analyst Price Targets for Fresenius SE & Co KGaA.

What is the consensus analysts' recommendation for Fresenius SE & Co KGaA?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co KGaA in the last year. There are currently 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fresenius SE & Co KGaA.

Has Fresenius SE & Co KGaA been receiving favorable news coverage?

Media coverage about FRE stock has been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fresenius SE & Co KGaA earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Fresenius SE & Co KGaA.

What other stocks do shareholders of Fresenius SE & Co KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius SE & Co KGaA investors own include Illumina (ILMN), Endologix (ELGX), Daimler (DAI), Cambrex (CBM), General Electric (GE), Linde (LIN), Rio Tinto (RIO), Apache (APA), Hudbay Minerals (HBM) and Centrica (CNA).

Who are Fresenius SE & Co KGaA's key executives?

Fresenius SE & Co KGaA's management team includes the folowing people:
  • Gerd Krick, Chairman of the Supervisory Board
  • Stephan Sturm, Chief Executive Officer (Age 52)
  • Niko Stumpfoegger, Deputy Chairman of the Supervisory Board, Employee Representative
  • Juergen Goetz, Chief Legal and Compliance Officer, Labor Relations Director, Member of the Management Board
  • Francesco De Meo, Member of the Management Board, Chief Executive Officer of Fresenius Helios
  • Mats Christer Henriksson, Member of the Management Board, Chief Executive Officer Fresenius Kabi
  • Rice Powell, Member of the Management Board, Chief Executive Officer of Fresenius Medical Care (Age 61)
  • Ernst Wastler, Member of the Management Board, Chief Executive Officer Fresenius Vamed
  • D. Michael Albrecht, Member of the Supervisory Board
  • Michael Diekmann, Member of the Supervisory Board (Age 63)

What is Fresenius SE & Co KGaA's stock price today?

One share of FRE stock can currently be purchased for approximately €48.39.

What is Fresenius SE & Co KGaA's official website?

The official website for Fresenius SE & Co KGaA is http://www.fresenius.de/.

How can I contact Fresenius SE & Co KGaA?

Fresenius SE & Co KGaA's mailing address is Else-Kroener-Str. 1, BAD HOMBURG VOR DER HOEHE, 61352, Germany. The company can be reached via phone at +49-6172-6080.


MarketBeat Community Rating for Fresenius SE & Co KGaA (FRA FRE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Fresenius SE & Co KGaA and other stocks. Vote "Outperform" if you believe FRE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel